(Q36746817)

English

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

scientific article published on 28 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

phase I clinical trial

0 references

protein ubiquitination

1 reference

based on heuristic

inferred from title

Craig W. Beattie

10

object named as

C W Beattie

0 references

author name string

M A Warso

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

J M Richards

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

D Mehta

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

K Christov

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

C Schaeffer

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

L Rae Bressler

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

T Yamada

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

D Majumdar

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

S A Kennedy

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

T K Das Gupta

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

28 February 2013

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

108

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1061-1070

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Noncationic peptides obtained from azurin preferentially enter cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

A strategic framework for novel drug development in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

How to design a phase I trial of an anticancer botanical.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Unconventional anticancer agents: a systematic review of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Human cytochrome c enters murine J774 cells and causes G1 and G2/M cell cycle arrest and induction of apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Bacterial redox protein azurin induce apoptosis in human osteosarcoma U2OS cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Rescuing the function of mutant p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Natural products in anticancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

BCG immunotherapy of bladder cancer: 20 years on.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

29 September 2017

Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

28 June 2018

Keeping the immune system alerted against cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

28 June 2018

Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

5 September 2018

[Cytotoxicity and apoptosis of human osteosarcoma U2OS cells induced by recombinant soluble AZURIN].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

5 September 2018

The IARC TP53 database: new online mutation analysis and recommendations to users

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619084

5 September 2018

Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.74

21 January 2018

Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.74

21 January 2018

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.74

21 January 2018

METASTATIC MELANOMA OF THE GASTROINTESTINAL TRACT

1 reference

https://pubmed.ncbi.nlm.nih.gov/23449360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23449360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23449360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/23449360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Selective inducement effect of bacterial redox protein azurin on apoptosis of human osteosarcoma cell line U2OS]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23449360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2013.74

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36746817&oldid=2199267735"